Research programme: hyperphosphataemia therapy - OPKO Health
Alternative Names: CTAA101 Capsules; CTAA102 CapsulesLatest Information Update: 04 Nov 2017
At a glance
- Originator Cytochroma
- Developer OPKO Health
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hyperphosphataemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperphosphataemia in USA (PO, Capsule)
- 04 Mar 2013 Cytochroma has been acquired by OPKO Health
- 10 Jan 2007 Preclinical trials in Hyperphosphataemia in Canada (PO)